BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 23799547)

  • 21. Rosuvastatin, a new generation 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, reduces ischemia/reperfusion-induced spinal cord tissue injury in rats.
    Ucak A; Onan B; Güler A; Sahin MA; Kılıçkaya O; Oztaş E; Uysal B; Arslan S; Yılmaz AT
    Ann Vasc Surg; 2011 Jul; 25(5):686-95. PubMed ID: 21724106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. YQWY decoction reverses cardiac hypertrophy induced by TAC through inhibiting GATA4 phosphorylation and MAPKs.
    Huang JJ; Xie Y; Li H; Zhang XX; Huang Q; Zhu Y; Gu P; Jiang WM
    Chin J Nat Med; 2019 Oct; 17(10):746-755. PubMed ID: 31703755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The therapeutic effect of rosuvastatin on cardiac remodelling from hypertrophy to fibrosis during the end-stage hypertension in rats.
    Zhang WB; Du QJ; Li H; Sun AJ; Qiu ZH; Wu CN; Zhao G; Gong H; Hu K; Zou YZ; Ge JB
    J Cell Mol Med; 2012 Sep; 16(9):2227-37. PubMed ID: 22288611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 3-HMG-Coenzyme A reductase inhibition and extracellular matrix gene expression in the pressure-overloaded rat heart.
    Cirrincione GM; Boluyt MO; Hwang HS; Bleske BE
    J Cardiovasc Pharmacol; 2006 Apr; 47(4):521-30. PubMed ID: 16680065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway.
    Irukayama-Tomobe Y; Miyauchi T; Sakai S; Kasuya Y; Ogata T; Takanashi M; Iemitsu M; Sudo T; Goto K; Yamaguchi I
    Circulation; 2004 Feb; 109(7):904-10. PubMed ID: 14967736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rosuvastatin attenuates Ang II--mediated cardiomyocyte hypertrophy via inhibition of LOX-1.
    Kang BY; Mehta JL
    J Cardiovasc Pharmacol Ther; 2009 Dec; 14(4):283-91. PubMed ID: 19724024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rosuvastatin elicits KDR-dependent vasculogenic response of human placental stem cells through PI3K/AKT pathway.
    Cantoni S; Cavallini C; Bianchi F; Bonavita F; Vaccari V; Olivi E; Frascari I; Tassinari R; Valente S; Lionetti V; Ventura C
    Pharmacol Res; 2012 Mar; 65(3):275-84. PubMed ID: 22207243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ovariectomy augments pressure overload-induced hypertrophy associated with changes in Akt and nitric oxide synthase signaling pathways in female rats.
    Bhuiyan MS; Shioda N; Fukunaga K
    Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1606-14. PubMed ID: 17878225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine.
    Kang BY; Wang W; Palade P; Sharma SG; Mehta JL
    J Cardiovasc Pharmacol; 2009 Oct; 54(4):327-34. PubMed ID: 19687748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Downregulation of survival signalling pathways and increased apoptosis in the transition of pressure overload-induced cardiac hypertrophy to heart failure.
    Li XM; Ma YT; Yang YN; Liu F; Chen BD; Han W; Zhang JF; Gao XM
    Clin Exp Pharmacol Physiol; 2009 Nov; 36(11):1054-61. PubMed ID: 19566828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The acute phase protein alpha2-macroglobulin induces rat ventricular cardiomyocyte hypertrophy via ERK1,2 and PI3-kinase/Akt pathways.
    Padmasekar M; Nandigama R; Wartenberg M; Schlüter KD; Sauer H
    Cardiovasc Res; 2007 Jul; 75(1):118-28. PubMed ID: 17412314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Roles of cyclooxygenase-2 and phosphorylated Akt (Thr308) in cardiac hypertrophy regression mediated by left-ventricular unloading.
    Wohlschlaeger J; Schmitz KJ; Palatty J; Takeda A; Takeda N; Vahlhaus C; Levkau B; Stypmann J; Schmid C; Schmid KW; Baba HA
    J Thorac Cardiovasc Surg; 2007 Jan; 133(1):37-43. PubMed ID: 17198778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy.
    Chang SA; Kim YJ; Lee HW; Kim DH; Kim HK; Chang HJ; Sohn DW; Oh BH; Park YB
    Hypertension; 2009 Sep; 54(3):591-7. PubMed ID: 19564547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombomodulin is upregulated in cardiomyocytes during cardiac hypertrophy and prevents the progression of contractile dysfunction.
    Li YH; Chung HC; Luo CY; Chao TH; Shyu KG; Shi GY; Wu HL
    J Card Fail; 2010 Dec; 16(12):980-90. PubMed ID: 21111988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome.
    Hermida N; Markl A; Hamelet J; Van Assche T; Vanderper A; Herijgers P; van Bilsen M; Hilfiker-Kleiner D; Noppe G; Beauloye C; Horman S; Balligand JL
    Cardiovasc Res; 2013 Jul; 99(1):44-54. PubMed ID: 23542580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Simvastatin attenuated cardiac hypertrophy via inhibiting JAK-STAT pathways].
    Wu Y; Liu J
    Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Aug; 36(8):738-43. PubMed ID: 19100119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. C-C chemokine receptor 5 signaling contributes to cardiac remodeling and dysfunction under pressure overload.
    Wang X; Li W; Yue Q; Du W; Li Y; Liu F; Yang L; Xu L; Zhao R; Hu J
    Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33200795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quercetin Prevents In Vivo and In Vitro Myocardial Hypertrophy Through the Proteasome-GSK-3 Pathway.
    Chen K; Rekep M; Wei W; Wu Q; Xue Q; Li S; Tian J; Yi Q; Zhang G; Zhang G; Xiao Q; Luo J; Liu Y
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):5-21. PubMed ID: 29435775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rosuvastatin-regulated post-translational phosphoproteome in human umbilical vein endothelial cells.
    Huang B; Wu CH; Li FA; Liang SS; Shieh YH; Wang LD
    Kaohsiung J Med Sci; 2013 Jul; 29(7):347-52. PubMed ID: 23768697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pinoresinol diglucoside (PDG) attenuates cardiac hypertrophy via AKT/mTOR/NF-κB signaling in pressure overload-induced rats.
    Chen Y; Pan R; Zhang J; Liang T; Guo J; Sun T; Fu X; Wang L; Zhang L
    J Ethnopharmacol; 2021 May; 272():113920. PubMed ID: 33607200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.